Abstract
Legal context This article examines the non-use and unreasonable use of technology patented under the US Bayh-Dole Act which allows the private sector to retain ownership to patent title generated using federal funds.
Key points The article highlights the failure of the US to apply the protective measures granted under the Act to shield the public from “extraordinary” price increase in innovative prescription drugs which had benefited from significant federal funding.
Practical significance The article suggests alternative methods that may be used in order to ensure that the public acquires affordable medication in cases where the drugs were developed using federal funds
Key points The article highlights the failure of the US to apply the protective measures granted under the Act to shield the public from “extraordinary” price increase in innovative prescription drugs which had benefited from significant federal funding.
Practical significance The article suggests alternative methods that may be used in order to ensure that the public acquires affordable medication in cases where the drugs were developed using federal funds
| Original language | English |
|---|---|
| Pages (from-to) | 874-892 |
| Journal | Journal of Intellectual Property Law and Practice |
| Volume | 5 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - 01 Oct 2010 |